Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844939 | 1.00 | KDM4E (0.46) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3367902 | 0.87 | KDM4E (0.63) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3367895 | 0.87 | KDM4E (0.63) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3370337 | 0.77 | ALDH1A1 (0.56) | KDM4EACHEKMT2AALDH1A1CYP3A4 | |
| SCHEMBL3370335 | 0.77 | ALDH1A1 (0.56) | KDM4EACHEKMT2AALDH1A1CYP3A4 | |
| SCHEMBL3402759 | 0.74 | KDM4E (0.59) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3402763 | 0.74 | KDM4E (0.59) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3371855 | 0.74 | KDM4E (0.61) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL3371851 | 0.74 | KDM4E (0.61) | KDM4ELMNAACHEKMT2AMEN1 | |
| SCHEMBL14528991 | 0.70 | MEN1 (0.36) | KDM4ELMNAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838707-B1 | NOVEL PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080161338-A1 | Novel Pyrrolodihydroisoquinolines as Pde 10 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1838707-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | Nycomed GmbH (DE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006089815-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161338-A1 | Novel Pyrrolodihydroisoquinolines as Pde 10 Inhibitors | PDE12, PDE5A, PDE3A | KDM4E 202/4885LMNA 3839/4885ACHE 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.